PTGX Protagonist Therapeutics, Inc.data gap · 80% coverage
Health Care · Biotechnology · close $128.75 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Protagonist Therapeutics, Inc. (PTGX) has a ThetaGrade House Rating of 71/100 (grade B), ranking #97 of 150 in Health Care. Its strongest pillars are balance sheet (98) and growth (83); its weakest is valuation (7). Data gap: 4 factors without usable data, so 80% of the method weight is covered. TTM revenue growth is 34.8% and operating margin 20.7%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change, Interest coverage. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 80% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 83| Revenue growth YoY (TTM) (13.3%) | 34.8% | 84 |
| EPS growth YoY (TTM) (13.3%) | 41.1% | 74 |
| Revenue acceleration (6.7%) | 3650.1% | 100 |
Profitability
weight 18.5% (→20.0%) · 72| Operating margin (20.0%) | 20.7% | 72 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 98| Net debt / EBITDA (13.3%) | -6.88× | 99 |
| Current ratio (6.7%) | 21.71 | 96 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 65| FCF margin (6.7%) | 121.9% | 100 |
| FCF yield (6.7%) | 0.7% | 29 |
Valuation
weight 12.33% (→13.3%) · 7| P/E (inverted) (6.7%) | 125.00× | 6 |
| EV/Sales (inverted) (6.7%) | 28.09× | 7 |
Technicals (EOD)
| RSI(14) | 31.5 |
| EMA 9 / 21 | 137.33 / 139.91 |
| 200-day SMA | 113.77 |
| Volume vs 20d avg | 1.01× |
| 20-day return | -10.4% |
Exit-rule monitor
No exit or watch rules triggered.
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like PTGX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is PTGX's House Rating?
- PTGX scores 71 out of 100 (grade B) as of 2026-10-16, ranking #97 of 150 Health Care stocks we cover.
- What do analysts say about PTGX?
- We do not have enough analyst-sentiment data to score this stock.
- When does PTGX report earnings next?
- PTGX's next earnings report is estimated for about 2026-11-05 (window 2026-10-31 to 2026-11-10), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is PTGX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology